Literature DB >> 7571211

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program.

M J Barry1, C Fleming, C M Coley, J H Wasson, M C Fahs, J E Oesterling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7571211     DOI： 10.1016/S0090-4295(99)80255-6

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  5 in total

1.  Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.

Authors:  P S Bunting; V Goel; J I Williams; N A Iscoe
Journal:  CMAJ       Date:  1999-01-12       Impact factor: 8.262

2.  Cost-effectiveness analysis of prostate cancer screening.

Authors:  C Hamashima; K Yoshida
Journal:  Environ Health Prev Med       Date:  2000-10       Impact factor: 3.674

3.  Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.

Authors:  E A M Heijnsdijk; T M de Carvalho; A Auvinen; M Zappa; V Nelen; M Kwiatkowski; A Villers; A Páez; S M Moss; T L J Tammela; F Recker; L Denis; S V Carlsson; E M Wever; C H Bangma; F H Schröder; M J Roobol; J Hugosson; H J de Koning
Journal:  J Natl Cancer Inst       Date:  2014-12-13       Impact factor: 13.506

4.  Prostate cancer in elderly men.

Authors:  Anton Stangelberger; Matthias Waldert; Bob Djavan
Journal:  Rev Urol       Date:  2008

5.  Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.

Authors:  Nikolai Mühlberger; Kristijan Boskovic; Murray D Krahn; Karen E Bremner; Willi Oberaigner; Helmut Klocker; Wolfgang Horninger; Gaby Sroczynski; Uwe Siebert
Journal:  BMC Public Health       Date:  2017-06-26       Impact factor: 3.295
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.